Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors

Journal of Cardiology

Volumn 66, Issue 1, 2015, Pages 22-27

  Pello, Ana María ^a   Cristóbal, Carmen ^b,c   Tarín, Nieves ^d   Huelmos, Ana ^e   Aceña, Álvaro ^a   Carda, Rocío ^a   González Casaus, María Luisa ^f   Alonso, Joaquín ^b,c   Lorenzo, Óscar ^a,g   Blanco Colio, Luis ^a   Martín Ventura, José Luis ^a,g   Franco Peláez, Juan Antonio ^a   Mahíllo Fernández, Ignacio ^a   Farré, Jerónimo ^a,g   López Bescós, Lorenzo ^c   Egido, Jesús ^a,g,h   Tuñón, José ^a,g  

^a 28400 Madrid   (Spain)

^b HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^c UNIVERSIDAD REY JUAN CARLOS   (Spain)

^d HOSPITAL DE MÓSTOLES   (Spain)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^f HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^g UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Atherosclerosis; Biomarkers; Cardiovascular risk factors; Fibroblast growth factor 23; Monocyte chemoattractant protein 1

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CALCIDIOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR 23; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; VITAMIN D; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CALCIFEDIOL; CCL2 PROTEIN, HUMAN; CHOLESTEROL; FIBROBLAST GROWTH FACTOR; GALECTIN 3; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PARATHYROID HORMONE; PEPTIDE FRAGMENT; PHOSPHATE; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; INFLAMMATION; ISCHEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; PROGNOSIS; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; METABOLISM; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RISK FACTOR;

BIOMARKERS; C-REACTIVE PROTEIN; CALCIFEDIOL; CHEMOKINE CCL2; CHOLESTEROL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; GALECTIN 3; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PHOSPHATES; PROGNOSIS; RISK FACTORS; TRIGLYCERIDES;

EID: 84930927058     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2014.11.006     Document Type: Article

References (35)

1. Ridker P.M., Libby P. Risk markers for atherothrombotic disease. Braunwald's heart disease. A textbook in cardiovascular medicine 2012, 914-934. Elsevier, Philadelphia. 9th ed. R.O. Bonow, D.L. Mann, D.P. Zipes, P. Libby (Eds.).
2. Ridker P.M., Glynn R.J., Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998, 97:2007-2011.
3. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
4. de Lemos J.A., Morrow D.A., Sabatine M.S., Murphy S.A., Gibson C.M., Antman E.M., McCabe C.H., Cannon C.P., Braunwald E. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003, 107:690-695.
5. Tuñón J., Blanco-Colio L., Cristóbal C., Tarín N., Higueras J., Huelmos A., Alonso J., Egido J., Asensio D., Lorenzo O., Mahíllo-Fernández I., Rodríguez-Artalejo F., Farré J., Martín-Ventura J.L., López-Bescós L. Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease. Am J Cardiol 2014, 113:434-440.
6. Di Angelantonio E., Chowdhury R., Sarwar N., Ray K.K., Gobin R., Saleheen D., Thompson A., Gudnason V., Sattar N., Danesh J. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009, 120:2177-2187.
7. Lok D.J., Van Der Meer P., de la Porte P.W., Lipsic E., Van Wijngaarden J., Hillege H.L., van Veldhuisen D.J. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010, 99:323-328.
8. Dumic J., Dabelic S., Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006, 1760:616-635.
9. Ketteler M., Wolf M., Hahn K., Ritz E. Phosphate: a novel cardiovascular risk factor. Eur Heart J 2013, 34:1099-1101.
10. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 2010, 21:1427-1435.
11. Lavie C.J., Lee J.H., Milani R.V. Vitamin D and cardiovascular disease will it live up to its hype?. J Am Coll Cardiol 2011, 58:1547-1556.
12. van Ballegooijen A.J., Reinders I., Visser M., Brouwer I.A. Parathyroid hormone and cardiovascular disease events: a systematic review and meta-analysis of prospective studies. Am Heart J 2013, 165:655-664.
13. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Böhm M., Christiaens T., Cifkova R., De Baer G., Dominiczak A., Galderisi M., Grobbee D.E., Jaarsma T., Kirchhof P., Kjeldsen S.E., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013, 34:2159-2219.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
15. Otaki Y., Gransar H., Berman D.S., Cheng V.Y., Dey D., Lin F.Y., Achenbach S., Al-Mallah M., Budoff M.J., Cademartiri F., Callister T.Q., Chang H.J., Chinnaiyan K., Chow B.J., Delago A., et al. Impact of family history of coronary artery disease in young individuals (from the CONFIRM registry). Am J Cardiol 2013, 111:1081-1086.
16. Rydén L., Grant P.J., Anker S.D., Berne C., Cosentino F., Danchin N., Deaton C., Escaned J., Hammes H.P., Huikuri H., Marre M., Marx N., Mellbin L., Ostergren J., Patrono C., et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013, 34:3035-3087.
17. Khot U.N., Khot M.B., Bajzer C.T., Sapp S.K., Ohman E.M., Brener S.J., Ellis S.G., Lincoff A.M., Topol E.J. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290:898-904.
18. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., McQueen M., Budaj A., Pais P., Varigos J., Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
19. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
20. Cesari M., Penninx B.W., Newman A.B., Kritchevsky S.B., Nicklas B.J., Sutton-Tyrrell K., Rubin S.M., Ding J., Simonsick E.M., Harris T.B., Pahor M. Inflammatory markers and onset of cardiovascular events: results from the health ABC study. Circulation 2003, 108:2317-2322.
21. Dawber T.R., Moore F.E., Mann G.V. Coronary heart disease in the Framingham study. Am J Public Health Nations Health 1957, 47:4-24.
22. Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden C., Budaj A., Bugiardini R., Crea F., Cuisset T., Di Mario C., Ferreira J.R., Gersh B.J., Gitt A.K., Hulot J.S., Marx N., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013, 34:2949-3003.
23. Inoue S., Egashira K., Ni W., Kitamoto S., Usui M., Otani K., Ishibashi M., Hiasa K., Nishida K., Takeshita A. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 2002, 106:2700-2706.
24. Nelken N.A., Coughlin S.R., Gordon D., Wilcox J.N. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991, 88:1121-1127.
25. Bustos C., Hernández-Presa M.A., Ortego M., Tuñón J., Ortega L., Pérez F., Díaz C., Hernández G., Egido J. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998, 32:2057-2064.
26. Schecter A.D., Rollins B.J., Zhang Y.J., Charo I.F., Fallon J.T., Rossikhina M., Giesen P.L., Nemerson Y., Taubman M.B. Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem 1997, 272:28568-28673.
27. Parker B.D., Schurgers L.J., Brandenburg V.M., Christenson R.H., Vermeer C., Ketteler M., Shlipak M.G., Whooley M.A., Ix J.H. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010, 152:640-648.
28. Scragg R., Jackson R., Holdaway I.M., Lim T., Beaglehole R. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol 1990, 19:559-563.
29. Syal S.K., Kapoor A., Bhatia E., Sinha A., Kumar S., Tewari S., Garg N., Goel P.K. Vitamin D deficiency, coronary artery disease, and endothelial dysfunction: observations from a coronary angiographic study in Indian patients. J Invasive Cardiol 2012, 24:385-389.
30. Watson K.E., Abrolat M.L., Malone L.L., Hoeg J.M., Doherty T., Detrano R., Demer L.L. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 1997, 96:1755-1760.
31. Gonzalez-Parra E., Rojas-Rivera J., Tuñón J., Praga M., Ortiz A., Egido J. Vitamin D receptor activation and cardiovascular disease. Nephrol Dial Transplant 2012, 27:17-21.
32. Tuñón J., Cristóbal C., Tarín N., Aceña Á., González-Casaus M.L., Huelmos A., Alonso J., Lorenzo Ó., González-Parra E., Mahíllo-Fernández I., Pello A.M., Carda R., Farré J., Rodríguez-Artalejo F., López-Bescós L., et al. Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease. PLOS ONE 2014, 9:e95402.
33. Sonoki K., Yoshinari M., Iwase M., Iino K., Ichikawa K., Ohdo S., Higuchi S., Iida M. Glycoxidized low-density lipoprotein enhances monocyte chemoattractant protein-1 mRNA expression in human umbilical vein endothelial cells: relation to lysophosphatidylcholine contents and inhibition by nitric oxide donor. Metabolism 2002, 51:1135-1142.
34. Rong J.X., Li J., Reis E.D., Choudhury R.P., Dansky H.M., Elmalem V.I., Fallon J.T., Breslow J.L., Fisher E.A. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 2001, 104:2447-2452.
35. Jain S.K., Micinski D. Vitamin D upregulates glutamate cysteine ligase and glutathione reductase, and GSH formation, and decreases ROS and MCP-1 and IL-8 secretion in high-glucose exposed U937 monocytes. Biochem Biophys Res Commun 2013, 437:7-11.